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Metaplasia in the Stomach Arises From Gastric Chief Cells
The development of intestinal-type gastric cancer is preceded
by loss of parietal cells (oxyntic atrophy) and the induction of
metaplastic cell lineages in the gastric mucosa. For example,
mouse models have shown that spasmolytic polypeptide-
expressing metaplasia can develop following oxyntic atrophy
through transdifferentiation of zymogen-secreting chief cells.
Evolution of spasmolytic polypeptide-expressing metaplasia
from chief cells occurs via a coordinated dismantling of their
secretory apparatus and reprogramming of their transcriptome.
Increasing evidence suggests that the process of chief cell
reprogramming requires the inﬂuence of inﬂammatory cyto-
kines and requires both zymogen granule autophagy and
alterations in gene transcription. It is likely that spasmolytic
polypeptide-expressing metaplasia is a physiological repair
mechanism that is similar to those that occur in other tissues
(eg, pancreas) for recruiting reparative progenitor cells
in response to mucosal wounds. Chronic inﬂammation can
induce a recurring pattern of persistent reprogramming/
metaplasia that increases the risk for neoplasia. (Cell Mol Gas-
troenterol Hepatol 2017;4:85–88; http://dx.doi.org/10.1016/
j.jcmgh.2017.03.006)
The most common type of gastric cancer, intestinaltype adenocarcinoma, almost always occurs in the
setting of metaplasia. Metaplasia in the stomach is thought
to be triggered by loss of acid-secreting parietal cell (oxyntic
atrophy). Although pathologists have long noticed that loss
of digestive-enzyme-secreting chief cells also occurs during
oxyntic atrophy, recent work has suggested that the 2 pro-
cesses are linked. Studies in mice with correlation to
humans1,2 have shown that chief cells may not simply die
during oxyntic atrophy. Rather, chief cells have the capacity
to respond to parietal cell death by reprogramming into
cells that fuel the metaplasia. Speciﬁcally, chief cells can
directly convert into metaplastic cells that express abundant
TFF2 (also known as spasmolytic polypeptide) in a process
known as spasmolytic polypeptide-expressing metaplasia
(SPEM).3 Thus, the zymogen-secreting chief cells in the body
of the stomach, although normally postmitotic, can exhibit
lineage plasticity during response to certain kinds of cancer-
predisposing injury. We summarize evidence for the role of
chief cell plasticity in the development of metaplasia.
Because of limitations on referencing in this commentary,
we cite only a few key publications, but it is hoped that
these lead readers to an evolving relevant literature.
The status of SPEM as a critical initial metaplasia in the
stomach was ﬁrst delineated in both human gastric re-
sections and in mouse models of Helicobacter infection.
These studies demonstrated the presence of SPEM in the
body of the stomach in concert with loss of parietal cells.1
The origin of SPEM was ﬁrst examined in models of acute
parietal cell loss using 2 drugs, DMP-777 and L635, which
induced acute parietal cell death because of their actions as
parietal cell-targeted protonophores.2 Similar ﬁndings were
then obtained based on parietal cell toxic effects of high-
dose tamoxifen administration.4 It is important to note
that several recent studies have increasingly supported the
concept that SPEM develops in the setting of gastric mucosal
injury, indicating that the metaplastic process is integral to
the healing response to acute injury.
Critical studies were performed in 2010 using Mist1-
CreERT2;LSL-LacZ mice to map lineages derived from chief
cells.2 Treatment with low-dose (non-metaplasia-inducing)
tamoxifen marked chief cells with expression of b-galactosi-
dase. In these studies, metaplasia was induced with both
acute drug-induced models (DMP-777 and L635) and by
infection with Helicobacter. felis for 9 months. In all 3 cases,
the TFF2-expressing SPEM that developed was marked with
b-galactosidase expression, indicating that these metaplastic
lineages were largely derived from chief cells. These lineage
mapping studies were the ﬁrst direct evidence for a process
that reprogrammed chief cells into SPEM (Figure 1).
It should be recognized that the process of trans-
differentiationof chief cells ismarkedby clear cellular changes
required for such plasticity. These changes indicate an orderly
process of down-regulation of the zymogen secretion appa-
ratus and up-regulation of mucous granule secretion
(Figure 1).5 Following induction of acute oxyntic atrophy
(ie, as parietal cells die), chief cells show a rapid decrease in
the expression of the zymogen granule maturation tran-
scription factorMist1 (in the tamoxifen toxicity modelw90%
of gastric Mist1 mRNA is lost within 12 hours of a single
intraperitoneal injection). AsMIST1 is lost, there is an increase
in autophagic activity responsible for degradation of zymogen
granules (unpublished data).5 Subsequently, reprogramming
chief cells up-regulate a speciﬁc splice variant of CD44, CD44
variant 9 (by the human nomenclature), along with TFF2,
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MUC6, and other components of the mucous cell secretory
apparatus. These changes are coincident with the
up-regulation of several minichromosome maintenance pro-
teins,which induceunwindingof theDNA, a processnecessary
for reprogramming of the cell transcriptome during trans-
differentiation into SPEM.6 The reprogramming of the tran-
scriptome presumably facilitates the production of CD44v9,
and de novo MUC6 and TFF2-positive mucin granules.
We expect that the process of returning a postmitotic
chief cell back into a proliferative state will prove to be
highly regulated, and, indeed, we are just beginning to
scratch the surface of the various cellular and molecular
processes that govern this remarkable conversion. For
example, our recent ﬁndings indicate that as chief cells age
(>60 days old), they lose their ability to transdifferentiate
after induction of acute oxyntic atrophy.7 Hence, “younger”
chief cells (those arising more recently from the isthmal stem
cell) may be more plastic. Other recent studies in press
indicate that loss of parietal cells alone is not enough to
induce chief cell transdifferentiation, so there may be
multiple factors and cells involved in triggering this drastic
change in cell fate. In other studies now in press, we recently
performed a set of studies that highlighted both the complex
induction and the fact that there are multiple stages in
process of metaplasia induction: in interleukin (IL) 33, IL33
receptor, and IL13 knockout mice, despite profound parietal
cell loss after L635 treatment, transdifferentiation is blocked
until exogenous IL13 is administered. These studies and
others implicate IL13 release, likely from ILC2 cells, in the
initiation of chief cell plasticity changes. Furthermore, it is
clear that the reprogramming of a chief cell into a meta-
plastic cell requires multiple steps (degradation of zymogen
granules, expression of TFF2 and MUC6, and possible cell
cycle reentry), each of which, if blocked, can impede the
transdifferentiation process either during the phase of
dematuration or at the point of up-regulation of the mucus
secretory apparatus (Figure 1).5
Additionally, we have reported that expression in Mist1-
positive chief cells of a mutant form of K-Ras(G12D) that
leads to its constitutive activation (Mist1-KRas mice) causes
metaplasia.8 These studies supported numerous previous
studies that indicate that metaplasia largely emanates from
chief cells. Puzzlingly, using a similar model, Hayakawa et al9
came to a differing conclusion about the cell of origin: namely,
that only cells derived from the putative, constitutive stem
cell zone, the isthmus, contributed to metaplasia. Although
we do not rule out that some metaplastic cells may originate
from isthmal cells, we are convinced that chief cells are a key
cell-of-origin for metaplasia in the acute setting.
Next, we review systematically, the various experiments
that have led us to this conclusion. First, there is emerging
evidence that chief cells go through a well-choreographed,
sequence of deﬁnable stages en route to metaplasia, each of
which can be inhibited, resulting in a blockade of the meta-
plastic process. This process involves dematuration of the
chief cell with loss of Mist1-dependent zymogen differentia-
tion and degradation of zymogen granules, followed by
transdifferentiation to adopt a mucous cell secretory proﬁle
(Figure 1). These processes represent highly ordered tran-
sitions that are consistentwith a directed paradigmof cellular
plasticity rather than one of preparation for apoptosis.
Second, the isthmal contribution during SPEM can be
easily distinguished anatomically from the chief cell
contribution at the base or corpus glands. For example, the
original lineage mapping studies using DMP-777 demon-
strated that the phenotype of SPEM in mice was actually
composed of 2 different lineages.2 At the bases of glands,
TFF2-expressing SPEM cells were derived from chief cells
marked with Mist1-directed b-galactosidase expression.
However, TFF2-expressing cells in the mid-gland did not
Figure 1. Schematic for transdifferentiation of chief cells into SPEM. Following loss of parietal cells (eg, with Heli-
cobacter pylori infection or parietal cell toxic drugs), chief cells down-regulate their zymogen secretory apparatus
(concomitant with loss of the master regulator of the secretory apparatus, the transcription factor MIST1). This decrease in
chief cell mature phenotype (dematuration) is followed by reprogramming of the chief cell transcriptome to complete
transdifferentiation into SPEM. Note that this model does not necessarily rule out a contribution to SPEM from mucous
neck cells or even occasional isthmal cells, but the extant data strongly suggest that chief cell reprogramming is a major
source of metaplastic cells.
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express b-galactosidase, suggesting that they actually rep-
resented arrest of mucous neck cell differentiation into chief
cells. Because mucous neck cells reside between the isthmus
and the chief cell zone, this means that the SPEM cells at the
base of the glands most likely arose in the chief cell zone,
not the isthmus. Accordingly, we have previously demon-
strated evidence for 2 distinct foci of proliferation following
parietal cell loss: one representing expanding cells from the
isthmus, and the other representing reprogrammed chief
cells at the base with mucous neck cells in between.3 Only
injuries that induce metaplasia caused the basal chief cell
lineage-derived proliferation.
Third, although we also observe some isthmal cells
that mark with a reporter (eg, YFP) following low-dose
tamoxifen treatment of Mist1-Cre-expressing mice, their
occurrence is extremely rare (only 1 per 10–20 gland
units).7,8 Given that the metaplasia seen in Mist1-KRas
mice is essentially in every gland, it seems unlikely that
all these metaplastic lineages could be derived from isth-
mal cells.
Fourth, it is difﬁcult to conceive physiologically how, in
just 3 days (following L635 or high-dose tamoxifen) a small
number of isthmal cells could ﬁll an entire gland with mu-
cous neck cells and dozens of SPEM cells that extend all the
way to the base of the unit, while every other cell that had
previously resided in between the isthmus and base some-
how vanishes to make room for this column of newly arising
cells. Again, although we do not rule out contribution to
SPEM from the isthmus, it seems unlikely that the vast
extent of metaplasia across most of the corpus could be
accounted for by an origin only from rare marked isthmal
progenitors. An area of confusion may be in distinguishing
foveolar hyperplasia (certainly caused by overproliferation
of isthmal cells) from true metaplasia, wherein there are
basal proliferative cells that coexpress (low levels) of chief
cell markers with TFF2, CD44v9, and other markers of
SPEM. Indeed, several investigations including the recent
studies from Professor Ito’s group have demonstrated that
expression of K-Ras(G12D) in well-authenticated isthmal
progenitor cells leads to foveolar hyperplasia and not
metaplasia.10 These ﬁndings are consistent with previous
investigations of transforming growth factor-a over-
expression in Ménétrier’s disease that results in elevated
levels of phospho-ERK1/2 and preferential differentiation of
surface mucus cells from progenitor cells, a process that is
reversed following blockade of the epidermal growth factor
receptor with cetuximab.
Thus, although there is perhaps a better case for an
isthmal or mucous neck cell of origin for diffuse familial
gastric cancers that arise because of loss of E-cadherin
regulation in the stomach,9 the preponderance of evidence
suggests that metaplastic lineages that predispose to the
development of intestinal-type cancers have their origin in
large part via transdifferentiation of chief cells into meta-
plasia. Importantly, there is a clear analogy to another
metaplastic process in an organ without a constitutive stem
cell like the isthmal cell: in the pancreas, it has been well
established that MIST1-expressing, digestive-enzyme-
secreting acinar cells undergo a metaplasia analogous to
SPEM. This acinar to ductal metaplasia is thought to be the
origin of the preneoplastic pancreatic intraepithelial
neoplasia lesion in both mice and humans.5 The entire
sequence of acinar cells reprogramming from metaplasia
and thence into adenocarcinoma can also (and we ﬁnd this
unlikely to be coincidental) be driven by expressing mutant
K-Ras under control of Mist1. Thus, plasticity among acinar
cell populations may represent a general mechanism for
promoting healing within mucosae following local injury.
Chronic persistence of these metaplastic lesions in the face
of continuing inﬂammation may similarly represent a com-
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